Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients - Top-Institutions - MDSpire

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • By

  • Huan Xie

  • Maoyuan Xiang

  • Meijuan Zhang

  • Fanqiao Meng

  • Yan Qi

  • Kehong Chen

  • Dongfeng Zeng

  • June 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology

  • #2

    University Hospital of Salamanca
    University Hospital of Salamanca

    Salamanca, Spain

    Key Differentiators

    • Hematology

  • #3

    Daping Hospital, Army Medical University
    Daping Hospital, Army Medical University

    Chongqing, China

    Key Differentiators

    • Hematology

Original Source(s)

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • by Huan Xie, Maoyuan Xiang, Meijuan Zhang, Fanqiao Meng, Yan Qi, Kehong Chen, Dongfeng Zeng

  • June 23, 2026

Related Content

Endovascular thrombectomy in selected patients with active cancer and thrombocytopenia: outcomes under an institutional platelet transfusion practice

A Case Report of Primary Mucinous Adenocarcinoma of the Bladder and Literature Review

Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma